News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–58
Matches
58
Sources here
11
Companies here
1
Search results Stored financial headlines

Active search

58 matching headlines

Ticker or company: CRNXMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Earnings Main company 🇺🇸 United States

Crinetics Pharmaceuticals Inc (CRNX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Crinetics Pharmaceuticals Inc (CRNX), noting its current valuation score of 8.48, which ranks it 124th in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -16.33, comparing it to recent highs and lows. …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Crinetics Pharmaceuticals Inc (CRNX) Financial Health: Profitability & Balance Sheet Analysis

Crinetics Pharmaceuticals Inc (CRNX) has a current financial score of 7.15, ranking it 143 out of 384 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company recently reported a quarterly revenue of $10.73 million, marking a …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CRNX|Crinetics Pharmaceuticals Inc|Price:83.890|Chg%:+0.030

This article provides a comprehensive stock analysis of Crinetics Pharmaceuticals Inc (CRNX), highlighting its strong fundamentals, high growth potential, and current valuation. TradingKey's stock score places CRNX at 6th out of 384 in the Biotechnology & Medical Research industry. The company is performing strongly …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Crinetics Pharmaceuticals Inc (CRNX) Cash Flow

This article provides a detailed cash flow statement for Crinetics Pharmaceuticals Inc (CRNX), including operating, investing, and financing cash flows presented in both quarterly and annual formats. It highlights key financial figures such as operating cash flow of -377.92M in fiscal 2025 and capital …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Crinetics Pharmaceuticals Inc (CRNX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Crinetics Pharmaceuticals Inc. (CRNX) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock pricing and market capitalization information.

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Crinetics Pharmaceuticals Inc (CRNX) Income Statement

This article provides the quarterly and annual income statements for Crinetics Pharmaceuticals Inc (CRNX), detailing financial performance from FY2017Q1 to FY2026Q1. It includes metrics such as total revenue, operating expenses, R&D expenses, operating profit, net non-operating interest income/expenses, income before and after tax, and …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Crinetics Pharmaceuticals Inc (CRNX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Crinetics Pharmaceuticals Inc (CRNX), listing its major shareholders and their proportions. It also presents institutional holding trends over recent quarters, and identifies related ETFs that include CRNX. Top shareholders include Fidelity Management & Research Company LLC and …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Crinetics Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CRNX

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) generated $7.70 million USD in revenue last year, primarily from its Novel Therapeutics segment. The United States was the company's largest contributing region, accounting for the entire $7.70 million USD. This represents a significant increase from the previous year's …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CRNX|Crinetics Pharmaceuticals Inc|Price:83.989|Chg%:+0.339

Crinetics Pharmaceuticals Inc. (CRNX) has a current stock price of $83.73, with a market capitalization of $8.86 billion. The company, which specializes in therapeutics for rare endocrine diseases, exhibits strong fundamentals and high growth potential, despite being considered fairly valued by analysts. Institutional ownership …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇺🇸 United States

Vertex was sole bidder in high-premium Crinetics acquisition

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vertex Pharmaceuticals was the lone bidder in a planned, $10 billion acquisition that has some investors questioning whether the biotechnology giant overpaid …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

How Crinetics Pharmaceuticals Inc. (CRNX) Affects Rotational Strategy Timing

The article analyzes Crinetics Pharmaceuticals Inc. (CRNX) using AI models to provide insights for rotational strategy timing. It suggests a near-term neutral sentiment but mid and long-term strength for CRNX, with no clear price positioning signal and compelling upside potential due to a lack …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Crinetics Pharmaceuticals (NASDAQ: CRNX) backs $85-per-share cash sale to Vertex

Crinetics Pharmaceuticals' Board of Directors has unanimously approved an $85-per-share all-cash acquisition by Vertex Pharmaceuticals. The deal, which values Crinetics at an attractive premium, follows extensive negotiations and a review of strategic alternatives. Shareholders will vote on the merger, which is expected to close …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MLex Deals and strategy Main company 🇺🇸 United States

Vertex-Crinetics Pharmaceuticals deal faces Australian review

Australia's antitrust watchdog, the Australian Competition & Consumer Commission (ACCC), is reviewing Vertex Pharmaceuticals' proposed acquisition of Crinetics Pharmaceuticals. The ACCC is concerned about the deal's potential impact on competition, given Vertex's existing product offerings in Australia and Crinetics' single product, Palsonify, which is …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Market update Main company 🇺🇸 United States

Crinetics Pharmaceuticals (CRNX) Piper Sandler 36th Annual Healthcare Conference summary

Crinetics Pharmaceuticals presented at the Piper Sandler 36th Annual Healthcare Conference, highlighting advancements in their drug pipeline. Key updates include plans for an IND submission in 2025 for a Graves' disease and thyroid eye disease program, and an IND expected in early 2025 for …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

CRNX: Pipeline advances in acromegaly, CAH, and NETs, with strong financial runway into 2030

Crinetics Pharmaceuticals (CRNX) is making significant progress with its pipeline targeting major endocrine diseases, including strong launch metrics for PALSONIFY in acromegaly. The company's drugs Atumelnant and CRN09682 are moving forward in late-stage trials for CAH, Cushing's, and neuroendocrine tumors. With $1.3 billion in …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Deals and strategy Main company 🇺🇸 United States

Crinetics Pharmaceuticals (CRNX) R&D Day 2025 Summary

Crinetics Pharmaceuticals (CRNX) presented a summary of its R&D Day 2025, highlighting its strategic focus on endocrine and endocrine-adjacent diseases with a patient-centric approach. The company detailed its expanding pipeline, including paltusotine, atumelnant, CRN09682, a TSH antagonist (CRN12755) for Graves’ Disease, and an SST3 …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Deals and strategy Main company 🇺🇸 United States

Crinetics Pharmaceuticals (CRNX) Proxy filing Summary

Vertex Pharmaceuticals is set to acquire Crinetics Pharmaceuticals for approximately $10 billion ($8.8 billion net of cash), paying $85 per share in cash. This acquisition will bring PALSONIFY and atumelnant into Vertex's portfolio, with an expected combined peak annual revenue potential of over $5 …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
nasdaq.com Deals and strategy Main company 🇺🇸 United States

Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching

Key Points Vertex Pharmaceuticals' latest acquisition grants it access to products with $5 billion peak annual sales potential. The company's business is strong thanks to its dominance in its core market and new launches in other areas. 10 stocks we like better than Vertex …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sahm Earnings Main company 🇺🇸 United States

Crinetics Pharmaceuticals (CRNX) Stock Looks Fully Valued While Returns Stay Very Strong

Crinetics Pharmaceuticals (CRNX) has shown strong 5-year returns but its stock now appears fully valued, trading at a premium on traditional metrics, particularly its price-to-book ratio. Despite a proposed acquisition price of $85 per share and potential from its PALSONIFY and atumelnant programs, valuation …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sahm Deals and strategy Main company 🇺🇸 United States

Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85 per share, totaling approximately $10 billion. Despite the offer being slightly above the average analyst target, some investors believe there's still residual value, with a "most popular narrative" valuing the company at $90 …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Deals and strategy Main company 🇺🇸 United States

Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85 per share in an all-cash deal, valuing the acquisition at approximately $10 billion. The boards of both companies have unanimously approved the transaction, which is expected to close in Q3 of this year. …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
BioBuzz Deals and strategy Main company 🇺🇸 United States

Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Billion

Fortress Biotech has acquired Crinetics Pharmaceuticals for approximately $10 billion, significantly enhancing its presence in the rare endocrine disease market. Crinetics' stock surged 99% on the news, despite facing profitability challenges and insider selling activity. The acquisition, expected to close in Q3 2026, aims …

CRNX main company
Sharemaestro market context Trend signal active 52 weeks +173.9% CRNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context